Prognosis

Better heart failure outcomes through biomarker-based treatment

In a recent study by University of Alabama at Birmingham researchers, findings indicate that among patients with heart failure, obesity is associated with a higher risk of heart failure hospitalization or death due to cardiac causes.

However, achieving biomarker-based treatment goals in heart failure improves the prognosis for patients irrespective of their obesity status. 

The researchers published their findings in the Journal of the American Heart Association.

anatomical model of human heart
Anatomical model of a human heart

Image source: Unsplash/Robina Weermeijer

Heart failure is one of the leading causes of death in the United States and contributes to nearly 14 percent of all deaths in the U.S. Highly efficacious medications are now available for management of this disease.

Vibhu Parcha, M.D., a clinical research fellow in UAB’s Division of Cardiovascular Disease and the first author of this study, says obese individuals frequently have multiple comorbidities, which impacts how the heart functions; but paradoxically they were traditionally thought to have better prognosis in the setting of heart failure. “Obese individuals also have low circulating levels of beneficial heart hormones called natriuretic peptides that help control blood pressure and handling of salt,” Parcha said. “These hormones are increased in the setting of heart failure and are hence used as biomarkers for how badly the heart is doing. Previously it has been demonstrated that heart failure patients who regularly take their medications and have their NT-proBNP levels (a natriuretic peptide used as a heart failure biomarker) less than 1,000 pg/mL do better in terms of being admitted to hospital for worsening of heart failure or dying due to cardiac causes. 

Parcha and his investigative team analyzed heart failure patients enrolled in the NHLBI-sponsored Guiding Evidence-Based Therapy Using Biomarker-Intensified Treatment in Heart Failure, or GUIDE-IT, trial. “The assessment of heart failure patients in the setting of a randomized clinical trial allows us to look closely at how obesity impacts heart failure outcomes and whether good medical therapy can help improve outcomes for these patients,” Parcha said.  

It is important for us to convey to heart failure patients that their disease is manageable if they take their heart failure medications regularly and seek medical care

Pankaj Arora

Researchers found that, unlike the previously reported obesity paradox of heart failure, increasing body mass index was associated with a higher risk of heart failure hospitalizations for worsening heart failure or death from cardiac causes. They found that obese patients have nearly 60 percent lower levels of the natriuretic peptide-based biomarker NTproBNP, but still have worse outcomes. The important finding of the study was that, irrespective of obesity, if heart failure patients are adherent with their treatments and achieve an NTproBNP level of <1,000 pg/mL, they have nearly 50-70 percent lower risk of being hospitalized for heart failure or dying from cardiac reasons. “Heart failure is a serious medical condition, and all heart failure patients require close medical attention and care,” said senior author Pankaj Arora, M.D., a physician-scientist in the UAB’s Division of Cardiovascular Disease. “The diseased heart in conditions like heart failure produces higher levels of the natriuretic peptide hormones to restore normal functioning.” 

Arora added that the secretion of the hormone increases in an attempt to bring back normal function. “Obese individuals have very low levels of these beneficial hormones even during heart failure, and the low hormone levels are unable to compensate for the worsening heart failure,” Arora said. “They also have numerous comorbidities that predispose them to bad outcomes when they develop heart failure, as we noted in our study. The prior understanding of the obesity paradox — a better prognosis for obese people with heart failure — was based primarily on epidemiological studies. Obese patients may report heart failure symptoms early and hence are identified early in the disease course. Resultantly, the prior studies may have indicated a protective effect of obesity in heart failure.”  

Arora said researchers now have a huge arsenal of extremely effective medications that help physicians manage this disease. “Our study suggests that, irrespective of the obesity status of the heart failure patients, if we bring the NTproBNP biomarker levels to less than 1,000 pg/mL using these efficacious medications, we can cause a massive reduction in the risk of poor outcomes,” Arora said. “It is important for us to convey to heart failure patients that their disease is manageable if they take their heart failure medications regularly and seek medical care to ensure that their medications are being changed appropriately based on their health condition.” 


Source: University of Alabama at Birmingham

06.04.2021

Read all latest stories

Related articles

Photo

Fast Food study

More burger joints, more heart attacks

Areas with a higher number of fast food restaurants have more heart attacks, according to research presented at the 67th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand…

Photo

From the heart

Finding the 'fingerprint' of cardiovascular disease

Forty-two percent of all deaths in the United States are related to cardiovascular disease (CVD). According to the Global Cardiovascular Drugs Market Forecast, by 2030 the number of deaths from CVD…

Photo

Cardiology congress

ESC 2018: At the heart of research

When delegates from around 150 countries converge on Munich for ESC Congress 2018 they will no doubt reflect on what they themselves eat. Yes, nutrition is up for debate, questioning, for example,…

Related products

Alsachim, a Shimadzu group company – Dosinaco

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosinaco

Alsachim, a Shimadzu Group Company
Lifotronic - FA-160 Immunofluorescence Analyzer

Other

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter